Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
about
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivoAnnexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationAnnexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsA mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent modelsThe PCSK9 decadeNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesNew Era of Lipid-Lowering DrugsIn vivo evidence that furin from hepatocytes inactivates PCSK9The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.PCSK9 and Atherosclerosis - Lipids and Beyond.What lies ahead for the proprotein convertases?Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Local effects of human PCSK9 on the atherosclerotic lesion.Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cellsProprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Genetic and metabolic determinants of plasma PCSK9 levels.PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese peoplePCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.Decreased PCSK9 expression in human hepatocellular carcinoma.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levelsPeroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expressionDifferentiation of human foreskin fibroblast-derived induced pluripotent stem cells into hepatocyte-like cells.PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liverPlasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular eventsCombined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized RatsDecreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.PCSK9: a convertase that coordinates LDL catabolism.Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
P2860
Q21136366-F9F4C7A8-DBC0-4FA9-9117-3301DADD8CC8Q24294486-66762508-B13A-46E8-9A96-52028C670540Q24313575-6EE197A3-3052-4D16-B411-BCF4B71058D1Q24612184-DA7D77E3-0D54-4953-B71B-C87036D840E8Q24615397-61E131FB-605D-4E0F-AB4C-42E49170EC45Q26783407-674724ED-B4E7-4DA1-A2BC-ACB66D9FF8F4Q27009477-E420314C-A8CD-4861-8115-BD0F8768163CQ27655476-47B5FED7-9347-4363-BFB9-C1126042AD94Q28072298-AB84E9D1-72BA-4261-94C8-76BB0B9EF8D9Q28504537-9D90333A-64E3-49EB-8925-1A6AA4A24704Q30541820-C4A92FD1-0898-4763-B426-C2E1D982B46EQ32176120-6AD1F508-B0F9-4421-A534-DFF4CDBE6E08Q33675963-104E0824-9056-4C2E-B374-4C6FC2C78BC9Q34169463-DB39034D-52A7-4635-8A9D-F52667AB070CQ34430377-A55638BD-4FA4-4482-8393-E0D617A1476FQ34492178-3E095830-2BF4-4949-AE4D-FE1406D93A96Q34560763-B5DF8A31-E16B-46B0-A947-7F489FB60BDBQ34723257-6B9101F1-892A-4412-9226-2D84A2853ADEQ34857971-EC83C529-A44B-4480-897A-15864B8E4396Q34951227-02FDC8A9-47F1-4A41-974E-1AF2EBE7EFF8Q34974626-963CCBE1-25DF-4C37-88A0-4660BC83FDEBQ35036348-A9F114DD-CAEA-4B69-B90F-97CCA3C0ED84Q35436046-C54CA614-2077-4AD4-AE19-2E1995A0E247Q35653477-BA3D2D61-43CF-4EC1-A95A-E9D6EDA4EA66Q35870767-36B9403A-31DC-461A-B514-252A30D8D765Q35883857-3D680EFD-383C-42A0-BFF9-C9FABFBF4090Q35911079-132D9EF5-505F-4F6F-A12A-C3FBB45A8B99Q36078804-EEEEC303-536B-4FB6-97F6-2265935F2B81Q36115457-BFFA89FE-7CD7-4C2F-B676-E3A22E01C0B1Q36197840-2692C76E-2CF0-4423-BCF7-5C5A085057AEQ36281706-29BB7C2E-271B-47B2-9637-17AB9F37F97FQ36481769-7512E55F-BA64-4135-8F44-8DF79E91EC1CQ36506609-46A40783-48AF-4F56-B93D-E009B5DABFD9Q36520347-B116BAD5-DA76-442D-BF91-3D17FF6F37D7Q36520700-0C292552-17E9-4C0A-89A5-012335B961BDQ36554065-00BCE41D-0037-444C-9195-460838BE7119Q37115391-4F772C6C-9E79-4DC9-BA1A-ADC96E1BC4D5Q37116362-9952FA30-0B12-4320-AB83-19033DA7D113Q37173223-656B7A72-B90C-440E-86E0-6F159321E360Q37250324-9D00D719-5D28-4A59-A2A8-59382F60301D
P2860
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Proprotein convertase subtilis ...... e in mouse liver regeneration.
@en
type
label
Proprotein convertase subtilis ...... e in mouse liver regeneration.
@en
prefLabel
Proprotein convertase subtilis ...... e in mouse liver regeneration.
@en
P2093
P50
P356
P1433
P1476
Proprotein convertase subtilis ...... e in mouse liver regeneration.
@en
P2093
Ahmed Zaid
Ann Chamberland
Anna Roubtsova
Jadwiga Marcinkiewicz
Jean Davignon
Josée Hamelin
Michel Tremblay
Rachid Essalmani
Weijun Jin
P304
P356
10.1002/HEP.22354
P407
P577
2008-08-01T00:00:00Z